PharmaCyte Biotech, Inc. Appoints Linda S. Sher as its Chief Medical Officer
July 26, 2017 at 02:00 pm
Share
PharmaCyte Biotech, Inc. announced the appointment of Linda S. Sher, M.D. as the company’s Chief Medical Officer. Sher is a Professor of Clinical Surgery and Director of Clinical Research in the Division of Hepatobiliary and Pancreatic Surgery and Abdominal Organ Transplantation at the University of Southern California’s (USC) Keck School of Medicine. Dr. Sher is also the Chief of the Division of Clinical Research for the Department of Surgery where she oversees the implementation and conduct of clinical trials for the entire department, averaging between 50 and 70 studies at all times. She is also the Vice Chair of the USC Institutional Review Board. Sher will oversee the structure, conduct and reporting of PharmaCyte’s clinical trials and will represent PharmaCyte in its interactions with the company’s clinical trial investigators, regulatory agencies, key opinion leaders, the investment, medical and regulatory communities, as well as pharmaceutical and biotechnology sector collaborators and potential partners.
PharmaCyte Biotech, Inc. is a biotechnology company. It is focused on developing cellular therapies for cancer, diabetes, and malignant ascites based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. Its product candidate is referred to as CypCaps. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used to produce various biologically active molecules. It is advancing clinical research and development of new cellular-based therapies in oncology and diabetes. It is also focused on developing therapies for pancreatic and other solid cancerous tumors by using genetically engineered live human cells. Its product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. It is also focused on the benefits of the Cell-in-a-Box technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant.